GM Advisory Group LLC Purchases 500 Shares of Zoetis Inc. (NYSE:ZTS)

GM Advisory Group LLC increased its position in Zoetis Inc. (NYSE:ZTS) by 35.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,899 shares of the company’s stock after buying an additional 500 shares during the quarter. GM Advisory Group LLC’s holdings in Zoetis were worth $371,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in ZTS. Darwin Wealth Management LLC bought a new position in shares of Zoetis during the third quarter valued at $31,000. First Personal Financial Services acquired a new stake in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in Zoetis during the 3rd quarter worth $33,000. Quarry LP lifted its holdings in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. Finally, Fortitude Family Office LLC grew its position in shares of Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.2 %

Shares of NYSE ZTS opened at $176.98 on Friday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm has a market cap of $79.85 billion, a PE ratio of 33.27, a P/E/G ratio of 2.71 and a beta of 0.90. The company’s fifty day simple moving average is $185.62 and its 200 day simple moving average is $180.53. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 EPS. The business’s revenue was up 11.6% on a year-over-year basis. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis’s dividend payout ratio is 32.52%.

Analyst Ratings Changes

ZTS has been the subject of a number of analyst reports. Stifel Nicolaus raised their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Piper Sandler boosted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.